Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(04): 366-369
DOI: 10.1055/s-0041-1737011
Report on International Publication

Antiemetic Regimen with Olanzapine in Pediatric Patients Receiving Highly Emetogenic Chemotherapy

Azgar A. Rasheed 
1   Department of Medical Oncology, Dr. Bhimrao Ramji Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Sameer Bakhshi
1   Department of Medical Oncology, Dr. Bhimrao Ramji Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Chemotherapy-induced nausea and vomiting (CINV) are so significant and prevalent that the discovery of antiemetics was recently voted, by both physicians and patients alike, as one of the “Top 5 Advances in 50 Years of Modern Oncology.”[1] We recently published the results of a phase-III study which explored whether the addition of olanzapine to standard pediatric antiemetic regimens would improve their efficacy.[2]



Publication History

Article published online:
27 November 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Top 5 Advances in Modern Oncology. Available at: https://ascopost.com/issues/october-15-2014/top-5-advances- in-modern-oncology/. Accessed May 30, 2021
  • 2 Naik RD v S, Singh V, Pillai AS, Dhawan D, Bakhshi S. Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial. J Clin Oncol 2020; 38 (32) 3785-3793
    CrossrefPubMedGoogle Scholar
  • 3 Navari RM, Qin R, Ruddy KJ. et al Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 375 (02) 134-142
    CrossrefPubMedGoogle Scholar
  • 4 Hesketh PJ, Kris MG, Basch E. et al Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017; 35 (28) 3240-3261
    CrossrefPubMedGoogle Scholar
  • 5 Flank J, Robinson PD, Holdsworth M. et al Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer 2016; 63 (07) 1144-1151
    CrossrefPubMedGoogle Scholar
  • 6 Bakhshi S, Batra A, Biswas B, Dhawan D, Paul R, Sreenivas V. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2015; 23 (11) 3229-3237
    CrossrefPubMedGoogle Scholar
  • 7 Batra A, Bakhshi S. The safety and efficacy of aprepitant in combination with other antiemetic agents for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric patients. Expert Rev Qual Life Cancer Care 2016; 1 (03) 189-195
    CrossrefGoogle Scholar
  • 8 Sharma A, Ganguly S. CSK. et al Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: a randomised, open-label trial. BMJ Support Palliat Care 2020; (e-pub ahead of print). doi: DOI: 10.1136/bmjspcare-2020-002595.
    CrossrefPubMedGoogle Scholar
  • 9 Radhakrishnan V, Joshi A, Ramamoorthy J. et al Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: a double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer 2019; 66 (03) e27551
    CrossrefPubMedGoogle Scholar
  • 10 Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton symptom assessment scale. Cancer 2000; 88 (09) 2164-2171
    CrossrefPubMedGoogle Scholar
  • 11 Patel P, Robinson PD, Thackray J. et al Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediatr Blood Cancer 2017; 64 (10) e26542
    CrossrefPubMedGoogle Scholar
  • 12 Mehra N, Ganesan P, Ganesan TS. et al Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy. Med Oncol 2017; 35 (01) 12
    CrossrefPubMedGoogle Scholar
  • 13 Radhakrishnan V, Pai V, Rajaraman S. et al Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: an open-label, randomized phase 3 trial. Pediatr Blood Cancer 2020; 67 (09) e28532
    CrossrefPubMedGoogle Scholar
  • 14 Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9 (05) 188-195
    CrossrefPubMedGoogle Scholar
  • 15 Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L. et al The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract 2016; 3439707
    PubMedGoogle Scholar
  • 16 Shivaprakash G, Udupa KS, Sarayu V. et al Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: a prospective, nonrandomized, open-label study. Indian J Pharmacol 2017; 49 (06) 451-457
    CrossrefPubMedGoogle Scholar
  • 17 Chanthawong S, Lim YH, Subongkot S. et al Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Support Care Cancer 2019; 27 (03) 1109-1119
    CrossrefPubMedGoogle Scholar
  • 18 Chow R, Chiu L, Herrstedt J. et al Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Support Care Cancer 2021; 29 (08) 4269-4275
    CrossrefPubMedGoogle Scholar
  • 19 Pillai AK, Sharma KK, Gupta YK, Bakhshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 2011; 56 (02) 234-238
    CrossrefPubMedGoogle Scholar
  • 20 Ganguly S, Bakhshi S. Traditional and complementary medicine during COVID-19 pandemic. Phytother Res 2020; 34 (12) 3083-3084
    CrossrefPubMedGoogle Scholar
  • 21 Bansal M, Sharma KK, Vatsa M, Bakhshi S. Comparison of health-related quality of life of children during maintenance therapy with acute lymphoblastic leukemia versus siblings and healthy children in India. Leuk Lymphoma 2013; 54 (05) 1036-1041
    CrossrefPubMedGoogle Scholar
  • 22 Pramanik R, Agarwala S, Sreenivas V, Dhawan D, Bakhshi S. Quality of life in paediatric solid tumours: a randomised study of metronomic chemotherapy versus placebo. BMJ Support Palliat Care 2020; doi: DOI: 10.1136/bmjspcare-2020-002731.
    CrossrefPubMedGoogle Scholar